# US 2023/0390306 A1 · Methods of contraception using nomegestrol acetate and estradiol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390306 A1
- Document ID: US20230390306A1
- Status: Published application
- Kind: A1
- Application number: 18/031,749
- Filed: 2021-10-12
- Published: 2023-12-07
- Earliest claimed: 2020-10-16
- Assignees: Theramex Hq UK Limited
- Applicants: Theramex Hq UK Limited
- Inventors: Mitra BOOLELL
- Web page: https://patentgrep.com/patent/US20230390306A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 15/18: Feminine contraceptives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of contraception using as a first line combined oral contraceptive (COC), a COC composition comprising nomegestrol acetate (NOMAC) and estradiol or an ester thereof. Said COC compositions are associated with a lower risk of venous thromboembolism (VTE) as compared to other CHCs. The compositions may also be used in methods of treatment in women having conditions linked to menstruation and/or fertility.

## Claims

### Claim 1

A method of contraception, comprising:
(i) identifying a woman desirous of contraception as suitable for receiving a combined hormonal contraceptive (CHC);
(ii) selecting a CHC, wherein the selected CHC has been identified as a CHC associated with lowest risk of VTE, wherein the selected CHC is a combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof; and
(iii) providing the selected CHC associated with lowest risk of VTE for administration to the woman desirous of contraception.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising step (i-a) between steps (i) and (ii), wherein step (i-a) comprises:
(i-a) identifying a group of one or more CHCs associated with lowest risk of VTE, wherein the identified group of CHCs associated with lowest risk of VTE comprises: a combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof;
and wherein the selection in step (ii) is made from the group identified in step (i-a).

### Claim 3 (depends on 2)

The method according to claim 2, wherein in step (i-a) the CHCs identified as CHCs associated with lowest risk of VTE are the CHCs in the group comprising: a combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof, and one or more of a combined oral contraceptive (COC) composition comprising levonorgestrel, a combined oral contraceptive (COC) composition comprising norgestimate, and a combined oral contraceptive (COC) composition comprising norethisterone;
and wherein the selection in step (ii) is made from the group identified in step (i-a).

### Claim 4 (depends on 2, 3)

The method of claim 2 or 3, wherein in step (i-a) the CHCs identified as CHCs associated with lowest risk of VTE are the CHCs in the group comprising: a combined oral contraceptive (COC) comprising nomegestrol acetate and estradiol or an ester thereof; a combined oral contraceptive (COC) comprising levonorgestrel; a combined oral contraceptive (COC) comprising norgestimate; and a combined oral contraceptive (COC) comprising norethisterone.

### Claim 5

The method of any preceding claim, wherein in step (i) the woman desirous of contraception is identified as suitable for receiving a combined hormonal contraceptive (CHC) based on a determination of the VTE risk of the woman.

### Claim 6

The method of any preceding claim, wherein prior to step (i), the method comprises the step of determining the VTE risk of the woman desirous of contraception.

### Claim 7

The method of any preceding claim, wherein in step (i) the woman desirous of contraception is identified as suitable for receiving a combined hormonal contraceptive (CHC) based on a determination of the unintended pregnancy risk of the woman.

### Claim 8 (depends on 7)

The method of claim 7, wherein prior to step (i), the method comprises the step of determining the unintended pregnancy risk of the woman desirous of contraception.

### Claim 9

The method of any preceding claim, wherein the woman desirous of contraception has not been administered a combined oral contraceptive (COC) for at least 2 months.

### Claim 10

The method of any preceding claim, wherein the woman desirous of contraception has not been administered a combined hormone contraceptive (CHC) for at least 2 months.

### Claim 11

The method of preceding claim, wherein the woman desirous of contraception has not previously been administered a combined oral contraceptive (COC).

### Claim 12

The method of any preceding claim, wherein the woman desirous of contraception has not previously been administered a combined hormone contraceptive (CHC).

### Claim 13

The method of any preceding claim, wherein the woman desirous of contraception is not a woman at increased risk of VTE.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the woman desirous of contraception is as at increased risk of VTE.

### Claim 15

The method of any preceding claim, wherein the woman desirous of contraception is at increased risk of unintended pregnancy.

### Claim 16

The method according to any preceding claim, wherein the woman desirous of contraception is 35 years of age or above.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claims 1-15, wherein the woman desirous of contraception is less than 35 years of age.

### Claim 18

The method according to any preceding claim, wherein the woman desirous of contraception has a body mass index in excess of 30 kg/m2 and/or has diabetes.

### Claim 19

The method according to any preceding claim, wherein the woman desirous of contraception has a body mass index of 30 kg/m2 or less.

### Claim 20

The method according to any preceding claim, wherein the woman desirous of contraception does not have any condition in the list consisting of: cancer; systemic lupus erythematosus; haemolytic uraemic syndrome; chronic inflammatory bowel disease, optionally Crohn's disease or ulcerative colitis; and sickle cell disease.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the woman desirous of contraception has a condition selected from: cancer; systemic lupus erythematosus; haemolytic uraemic syndrome; chronic inflammatory bowel disease, optionally Crohn's disease or ulcerative colitis; and sickle cell disease.

### Claim 22

The method according to any preceding claim, wherein in the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration, the nomegestrol acetate and estradiol or ester thereof are present in the composition in a weight ratio of approximately 1.67 to 1.

### Claim 23

The method according to any preceding claim, wherein in the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration, the nomegestrol acetate is present in an amount ranging from about 1.5 mg to about 3.75 mg.

### Claim 24

The method according to any preceding claim, wherein in the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration, the estradiol or ester thereof is present in an amount ranging from about 0.5 mg to about 3 mg.

### Claim 25

The method according to any preceding claim, wherein in the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration, the estradiol is 17β-estradiol; optionally wherein the 17β-estradiol is in hemihydrate form.

### Claim 26

The method according to any preceding claim, wherein in the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration, the nomegestrol acetate is present in an amount of about 2.5 mg and the estradiol is present in an amount of about 1.5 mg.

### Claim 27

The method according to any preceding claim, wherein the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof is provided for administration daily for a period of 21 to 28 days; optionally for a period of 24 consecutive days.

### Claim 28

The method according to any preceding claim, wherein the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration is in the form of plain or film-coated tablets, sugar-coated tablets, soft gelatin capsules, wafer capsules, pills, cachets or powders.

### Claim 29

The method according to any preceding claim, wherein the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration further comprises at least one excipient selected from: lactose monohydrate; microcrystalline cellulose (E460); crospovidone (E1201); talc (E553b); magnesium stearate (E572); and colloidal anhydrous silica; or any combination thereof.

### Claim 30

The method according to any preceding claim, wherein the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration comprises: 2.5 mg nomegestrol acetate; 1.5 mg 17β-estradiol; 57.7 mg lactose monohydrate; 14 mg microcrystalline cellulose; 2.4 mg crospovidone; 0.7 mg talc; 0.7 mg magnesium stearate; and 0.44 mg colloidal anhydrous silica.

### Claim 31

The method according to any preceding claim, wherein the combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof provided for administration is provided as a pharmaceutical kit comprising a plurality of dosage units and optionally at least one placebo.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

Use of a composition comprising nomegestrol acetate and estradiol or an ester thereof in a method of contraception according to any one of claims 1-31.

### Claim 33

A composition for use in a method of treatment of a disease or condition, the method comprising the steps of:
(i) identifying a woman having the disease or condition to be treated as suitable for receiving a combined hormonal contraceptive (CHC);
(ii) Selecting a CHC, wherein the selected CHC has been identified as a CHC associated with lowest risk of VTE, wherein the selected CHC is a combined oral contraceptive (COC) composition comprising nomegestrol acetate and estradiol or an ester thereof; and
(iii) providing the selected CHC associated with lowest risk of VTE for administration to the woman to be treated,
wherein the disease or condition is selected from: painful menstrual bleeding; heavy and/or prolonged menstrual bleeding; acne; ovarian cysts; polycystic ovary syndrome; premenstrual syndrome; endometriosis; and premenstrual dysphoric disorder.

### Claim 34 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33)

A composition for use in a method according to claim 33, wherein the method of treatment comprises the features of the method of contraception defined in any of claims 2-31.
